Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid clearance may help identify nAMD patients who can maintain longer faricimab dosing intervals

April 7, 2026
3 min

The Ophthalmologist

Share

A post hoc analysis of the TENAYA and LUCERNE trials investigates the role of early retinal fluid resolution in predicting treatment intervals for patients with neovascular age-related macular degeneration (nAMD) undergoing faricimab therapy. Rapid resolution of intraretinal and subretinal fluid during the first 12 weeks is linked to extended dosing intervals up to every 16 weeks. The findings suggest that early anatomical responses could guide treatment strategies, potentially alleviating the treatment burden on patients and healthcare systems.